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Abstract
Systemic lupus erythematosus (SLE) is a progressive autoimmune disease associated with
widespread organ damage that can eventually cause death. Worldwide prevalence of SLE
is difficult to report mainly due to difficulty in diagnosis as a result of its heterogeneous
nature and nonspecific protean manifestations. Currently, circulating anti-DNA anti-
bodies are the most specific diagnostic biomarkers for SLE where many detection assays
are being employed in clinical practice. However, the diagnostic value of these techniques
is challenged by the detection of only subpopulations of these antibodies with varying
sensitivity and specificity. This is mainly attributed to differences in the antigen source
and presentation and in the employed reaction conditions. This chapter will thoroughly
discuss the technology, advantages, and limitations of each assay in addition to a special
focus on the recently developed diagnostic technologies and novel biomarkers. Moreover,
SLE will be presented as a disease model highlighting the importance of personalized
medicine.
Keywords: systemic lupus erythematosus, autoimmune disease, complex pathogenesis,
challenging diagnosis, anti-DNA antibodies, novel biomarkers, state-of-the-art diagnostic
technologies, personalized therapy
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease with many
unresolved questions regarding its pathogenesis, causes, best approaches for proper diagnosis
and therapy [1–3]. It is perhaps the most heterogeneous human disease where SLE patients
exhibit clinical manifestations that hugely vary on the levels of organ involvement and severity
that are accompanied by differential release of autoantibodies and other serological biomarkers
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[1, 4]. This is because the disease pathogenesis is highly chaotic and strikes any of the multiple
stages of the immune cascade resulting in extremely wide-ranging and difficult-to-predict clini-
cal and serological manifestations among SLE patients [1, 4]. As demonstrated through this
chapter, SLE challenges the clinical community in its diagnosis, prediction of the course of the
disease, extracting and monitoring reliable biomarkers, designing studies in clinical trials, and
developing new therapeutics [1, 3–5]. Owing to this highly heterogeneous nature of the disease,
SLE presents an ideal model for a disease that desperately calls for new developments in the
state-of-the-art diagnostic technologies that can detect highly specific and reliable new bio-
markers for disease diagnosis and prognosis, and it exemplifies the urge for personalized med-
icine that can target specific subsets of patients or specific organ involvement.
1.1. Epidemiology
Reporting on epidemiological data for SLE is not coherent among all countries, and the best
informative data are obtained from North America and Europe, while less documentation has
been received from Africa, Asia, Australia, and South America [1, 6]. Nevertheless, SLE is a
global disease in which its incidence, prevalence, time of onset, and mortality are highly
influenced by race and ethnicity [6]. For instance, in USA SLE has incidence and prevalence
rates that show great variability ranging from 2 to 7.6 per 100,000 per year and 19 to 159 per
100,000 per year, respectively [7, 8]. These variations can originate from differences in ethnicity,
race, and age within the studied SLE population and can also stem from differences in the
employed diagnostic criteria for SLE. Similar variation trends were also observed in some
European countries [9, 10].
One of the important characteristics of SLE is that it predominantly affects women more than
men [11] with a disease onset that is influenced by ethnic background. For instance, in a
different ethnic background-based study, it was found that the incidence of SLE in African-
Caribbean females is higher at younger ages than in Asian or Caucasian females [12]. This age-
specific incidence in females of different ethnicities was also seen in other studies performed in
different countries [13–15]. However, the reason behind this characteristic SLE predominance
in women more than in men is not entirely understood, but it was inferred to be related to
hormonal factors. For example, serum prolactin was found at higher levels in SLE patients
than a control group, but it is unknown how can prolactin be involved in SLE immune
deregulation. Independent of gender, it was reported that generally people of African origin
had a higher incidence of SLE than those of European origin [7, 8, 16].
Mortality risk is increased in SLE patients of Chinese, Hispanic, and African backgrounds with
strong associations of renal damage [17, 18]. This, however, might relate to the levels of disease
awareness and therapeutic adherence that might be different among different populations [6].
1.2. Pathophysiology
The chaos in biology associated with SLE, the involvement of multiple body organs along with
the release of a wide array of autoantibodies has definitely challenged the advancement in
understanding the disease pathophysiology. Such a comprehension is highly essential for the
Rapid Test - Advances in Design, Format and Diagnostic Applications64
identification of novel biomarkers, for efficient classification of SLE patients, and in exposing
specific pathways prone for targeting to help guiding personalized therapies [1, 4, 5]. Never-
theless, great insights have been achieved through the use of mouse models of lupus and
multiple genetic and epigenetic investigations [19–24] through which a mechanism for disease
development has been proposed to proceed as illustrated in Figure 1 [4].
Two important events set the basis for SLE pathophysiology: first is the loss of immune
tolerance in which the immune system acquires autoantigen recognition and second the
persistent release of autoantibodies that mainly target endogenous nucleic acids and associ-
ated proteins [1, 4]. A cascade of events has been postulated to underlie such two events and
comprise impaired disposal of apoptotic cells, accumulation and immune recognition of
nucleic acid material, deregulated lymphocyte signaling, and sustained production of inter-
ferons and other cytokines [1, 4].
Removal of apoptotic cell debris is normally a silent process. However, with impaired
elimination of dead cells as in SLE, nucleic acid material becomes vastly accumulated
and can acquire immunogenic properties through sustained exposure to the extracellular
Figure 1. Underlying immune deregulation in SLE pathogenesis. Accumulated nucleic acid material containing DNA,
RNA, and associated proteins that is released from apoptotic cells and neutrophils via NETosis can acquire immunogenic
properties through their sustained availability in the extracellular surrounding in addition to the co-association with
stimulatory molecules such as HGB1 protein. The accumulated nucleic acid material is engulfed by PCDs which in turn
activate intracellular TLRs that stimulate potent release of type I INFs from PDCs which stimulate expression of BAFF
that stimulates B-cell production of autoantibodies targeted against endogenous nucleic acids and associated proteins. T
cells are important key players in SLE pathogenesis as they induce the release of inflammatory cytokines such as IL-17
and mediate tissue injury and destruction. Furthermore, T-cell and B-cell interactions stimulate B-cell differentiation and
consequent release of pathogenic autoantibodies [4].
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environment and the association with immune-stimulatory molecules such as IL-1 and the
DNA-binding protein HMG-1 [25–27]. The innate immune cells plasmacytoid dendritic cells
(PDCs) act by engulfing apoptotic remains containing nucleic acid material which stimulates
the intracellular nucleic acid receptors Toll-like receptors (TLRs) particularly TLR7 and TLR9
[28–30]. When TLRs engage DNA or RNA, they elicit a strong release of type I interferons (IFNs)
such as IFN-α which in addition to other cytokines induce autoantibody production through
stimulating B-cell maturation and differentiation and can promote loss of immune tolerance and
impaired immune responses [31, 32]. The activation of B cells via type I INFs has also been
demonstrated by the increased expression of the B-cell-activating factor (BAFF) in response to
IFN-α which stimulates B-cell activation and generation of autoantibodies [33–36]. Released
autoantibodies bind their target antigens which are mainly nuclear components and form
immune complexes that are recognizable by PDCs and further stimulate the release of type I
IFNs amplifying INF signaling in a process known as “IFN signature” [1, 4, 27]. Many of the gene
products that become actively expressed in response to type I INFs are engaged in immunoreg-
ulatory functions and were found to be highly elevated in many SLE patients with strong
association of autoantibody release specifically those targeting RNA-binding proteins such as
RNP, Sm, Ro, and La [37]. TLR7 specifically binds single-stranded RNA and was found to be
strongly associated with the release of anti-Sm autoantibodies [38, 39]. On the other hand, TRL9
binds CpG-rich DNA sequences, was found to be highly expressed in B cells isolated from
patients with severe SLE activity with an association of potent release of anti-double-stranded
DNA (dsDNA) antibodies [38]. In addition to apoptotic cell death, neutrophil extracellular traps
that are rich in DNA released from neutrophil cell death (NETosis) and other immunosti-
mulatory molecules induce type I interferons through stimulating TLRs [40]. Impaired T-cell
signaling is also a significant contributor to SLE pathogenesis where overly activated T cells of
lupus were able to stimulate autoantibody production from B cells, activate dendritic cells, and
stimulate the release of inflammatory cytokines and can thus mediate widespread tissue injury
and inflammation [4, 41].
2. Biomarkers
A biomarker can be defined as an alteration in a cellular, molecular, genetic, epigenetic,
biochemical, biological, or other body events that specifically accompanies a disease or condi-
tion and is amenable for quantitative and qualitative analysis. Therefore, a biomarker can be
used for diagnostic, prognostic, and theranostic purposes, and the more specific it is for a
disease, the more reliable it becomes [5, 42]. In SLE, the search for novel and specific bio-
markers is highly crucial because as a disease of a huge range of clinical and serological
manifestations, it is challenging in so many levels including accurate diagnosis, predicting
disease progression, identification of disease flares, directing proper therapy, and for the
discovery of new treatments [5]. Owing to this tremendous heterogeneity, it is therefore
expected that no single biomarker for SLE can satisfy all the above purposes but the continu-
ous efforts in understanding SLE pathogenesis should accumulate informative data for the
discovery of novel and reliable biomarkers [43].
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The most commonly employed SLE biomarkers are antinuclear antibodies (ANAs) and anti-
DNA antibodies [43]. However, as will be described below, ANAs possess low specificity to
SLE due to their coexistence in other autoimmune diseases as well as in some healthy individ-
uals [44]. On the other hand, anti-DNA antibodies, despite being the most specific biomarkers
for SLE [27], have poor predictive values as their levels do not always parallel disease activity
[45]. Therefore, the search for novel biomarkers for SLE never ceased, and with the emergence
of newer detection technologies and the advances achieved in understanding SLE pathogene-
sis, new biomarkers have emerged from collective efforts of genetic, epigenetic, transcriptomic,
and proteomic studies as shall be described [46].
2.1. Antinuclear antibodies (ANAs)
ANAs are a large group of autoantibodies that target various nuclear antigens including DNA,
RNA, proteins, or complexes of nucleic acid and proteins [44]. They can generally be catego-
rized into two groups based on the targeted antigens, one group that recognizes DNA and
DNA-associated proteins such as histones or DNA-protein complexes such as nucleosomes
and another group that recognizes distinct proteins that exist in association with RNA and are
thus called RNA-binding proteins (RBPs) including the small nuclear ribonucleoproteins
(snRBPs) Sm, RNP, Ro, and La [47].
These nuclear antigens are normally enclosed within the nucleus. However, as described
above, upon cell death, these antigens are released into the extracellular space where they elicit
immune responses that lead to the generation of ANAs that target these antigens and form
immune complexes that further stimulate the immune system [4]. In the context of SLE, ANA
detection in patients’ sera is an important diagnostic criterion where they are specified as a
stand-alone criterion in SLE classification criteria that are used for SLE diagnosis [48–50] as
will be described in more details in the next section.
Although, ANA positivity is detected in not less than 95% of SLE patients [44, 51], they exhibit
low specificity to SLE as they are also detected in other autoimmune diseases including
rheumatoid arthritis, Sjogren’s syndrome, and mixed connective tissue disease [51, 52]. Fur-
thermore, depending on the employed detection method, ANA positivity can be seen in 20–
30% of healthy individuals in the general population for yet unknown reasons [44]. Therefore,
the value of ANA testing for SLE diagnosis is a debatable issue because of this diminished
specificity despite of its inclusion in SLE classification criteria [53].
2.2. Anti-DNA antibodies
Anti-DNA antibodies are a subgroup of ANAs that can recognize and bind cellular DNA, and
their detection is almost exclusive to SLE making them the serological hallmark for the disease
[27, 51, 54]. Whether anti-DNA antibodies are also released in the context of other human
diseases is a question that remains unanswered [27]. Detection of anti-DNA antibodies in the
sera of SLE patients has been included as a separate criterion in an optimized version of SLE
classification criteria that were set to enhance the sensitivity of the old criteria, as will be
described below, which highlights their importance for SLE diagnosis [50] as they exhibit 95%
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specificity for SLE and are detected in at least 70% of SLE patients [45]. In addition, their value
is not confined to their diagnostic role, but they are also quite valuable in probing the molec-
ular basis of lupus autoreactivity [27] and in theranostic investigations where they can be used
as deterministic factors for eligibility in clinical trials and in directing the clinical use of certain
therapeutics [55, 56]. In normal immune responses, antibodies that target DNA can be seen in
some cases such as that in response to viral or bacterial infections [54, 57]. However, anti-DNA
antibodies in normal immunity differ from SLE anti-DNA antibodies in many aspects. In
normal immunity, anti-DNA antibodies are of the IgM isotype that can recognize and bind
single-stranded DNA (ssDNA) with low affinity and are nonpathogenic in nature. But in SLE
pathogenesis, there is an isotype shift of the expressed anti-DNA antibodies from IgM to IgG
antibodies which are detected in the majority of SLE patients. These class-switched IgG anti-
bodies exhibit a high affinity toward double-stranded DNA that resulted from specific somatic
mutations in the variable regions of these antibodies mostly in the complementarity-determ-
ining regions (CDRs) that generated positively charged amino acid residues such as aspara-
gine, arginine, and lysine that promote enhanced binding affinity to the negatively charged
DNA [27, 54].
The origin of such IgG anti-DNA antibodies was suggested to derive from antigen-specific B-
cell clonal expansion where DNA was used as the selecting antigen [54]. However, the various
studies that investigated the release of high-affinity anti-DNA antibodies in SLE settled on the
prerequisite association of DNA with proteins to be able to elicit anti-DNA immune responses
[54, 58]. This implied a role for T cells that are reactive against histones, the proteins constitut-
ing octamer complexes around which stretches of DNA are wrapped inside the nucleus, and
nucleosomes which are the basic structural unit of chromatin [27, 54]. A mechanism was
proposed to start with presenting DNA in complexation with a foreign protein antigen (e.g.,
viral or bacterial) to T cells specific to this antigen. However, in a way that is not yet fully
characterized, a shift in recognition takes place toward the complexed DNA that triggers the
activation of T cells specific to histones and nucleosomes [27, 54].
Various studies have demonstrated differences in selectivity patterns exhibited between
anti-DNA antibodies of normal individuals and that of SLE patients. Normal anti-DNA
antibodies were found to exhibit high specificity toward species-specific DNA which
suggests that they bind at DNA regions that are not shared with human DNA. In contrast,
SLE anti-DNA antibodies were found to nonselectively bind to a variety of investigated
structurally different DNA antigens. This suggests that SLE anti-DNA antibodies might
specifically bind the highly conserved phosphate backbone rather than specific nucleotide
sequence [27, 54].
Therefore, as will be described later in the section of diagnostic technologies, assays that are
able to detect high-affinity anti-DNA antibodies are described as assays with high specificity to
SLE as it is inferred that such high-affinity anti-DNA antibodies are more reflective of SLE
immune-deregulated responses [27].
Despite this high specificity of anti-DNA antibodies to SLE, their value in disease prognosis is
compromised as they are poor predictors of disease activity [45]. This was demonstrated by
the detection of tenacious levels of anti-DNA antibodies in SLE patients in remission [59–61] or
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the presence of normal levels in patients with active disease [62]. Therefore, new biomarkers
are continuously emerging, and some of the promising biomarkers are discussed below. For
more detailed discussions, interested readers can be directed to these reviews [43, 46].
2.3. New spectrum of SLE biomarkers
2.3.1. Epigenetic biomarkers
Epigenetic biomarkers refer to the epigenetic changes that govern gene expression without
changing the nucleotide sequence of the DNA and are specifically associated with disease
development such as DNA methylation pattern, microRNA expression, and various histone
modifications [5]. In the case of SLE, certain epigenetic changes are detected in SLE patients
and can act as biomarkers such as the widespread DNA hypomethylation pattern in CD4 T
cells [63, 64] and DNA hypomethylation of the promoters of certain genes that encode immune
mediators and are associated with SLE pathogenesis such as CD40L [65], CD70 [66], perforin
[67], IL-10, and IL-13 [68, 69]. With reduced DNA methylation which normally acts as a
repressive signal, the affected genes become highly activated and consequently activate T and
B immune cells [5].
Another potential epigenetic biomarker for SLE is the aberrant changes in histone proteins
modification patterns that are normally quintessential for controlling gene expression [70, 71].
Specific changes in histone modifications have been observed in immune cells of SLE patients
[5] such as the widespread hypomethylation of lysine 9 residues in H3 histone protein in CD4
T cells [72].
In addition to histone modifications, changes in miRNA expression profile are promising SLE
biomarkers [5]. MiRNAs are short noncoding RNA sequences that regulate gene expression
via targeting and inhibiting mRNA transcripts [73]. It was recently discovered that miRNAs
play important roles in both innate and adaptive immune systems and are involved in the
pathogenesis of several autoimmune diseases including SLE [74–77]. Several studies have
aimed at profiling miRNA expression patterns in SLE and have identified several miRNAs
that were underexpressed in CD4 T cells isolated from SLE patients such as miRNA-146a [78,
79] and miRNA-125a [80]. Reduced levels of these miRNAs were inversely correlated with SLE
activity as they were associated with increased activation of type I interferon and inflamma-
tory chemokines, respectively.
2.3.2. Cytokines as potential biomarkers
As mentioned earlier with SLE pathophysiology, type I interferons and other cytokines exhibit
exacerbated activities in SLE and are key players in disease activity [1, 4]. Therefore, such
mediators represent potential biomarkers and well-validated therapeutic targets in SLE.
Cytokines with the most characterized roles in SLE pathology are those of type I interferon
pathway such as IFN-α and downstream-induced gene products. Aberrantly elevated levels of
INF-α have been detected in cerebrospinal fluid of patients with neuropsychiatric disease in
systemic lupus erythematosus in comparison to cerebrospinal fluid samples obtained from
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patients with other autoimmune diseases [81] and were suggested to contribute to disease
pathogenicity [82].
Using DNA microarray technology, the expression pattern of IFN-induced genes was found
to be highly elevated in peripheral blood mononuclear cells obtained from SLE patients
with severe disease state [83]. Positive correlation between IFN-induced genes and severity
of SLE clinical manifestations and multiple organ damage was also observed in other
studies [84, 85].
Among the most noticeable gene products that are regulated by type I interferons are IP-10
and sialic acid-binding Ig-like lectin 1 which were found to be associated with SLE pathoge-
nicity and were detected in highly elevated levels in many SLE patients [86, 87].
Many other cytokines have been detected in elevated levels in the sera of many SLE patients
and can thus represent potential biomarkers including IL-17 [88], IL-6, IL-10, IL-12, IL-15, and
IL-21 and others [5, 43].
3. Diagnosis
Diagnosis of SLE, according to the majority of clinicians, is best established upon combi-
natorial approach. Thus, a combination of patients’ clinical manifestations and laboratory
investigations that can comprise autoantibody assays, blood tests, cell cultures, certain
functional tests such as echocardiogram, or imaging such as neuroimaging must be
adopted [1, 51, 89]. The decision upon any of the aforementioned investigations is guided
by the patient’s clinical presentations [51]. In addition, other important factors must be
examined including patient’s history, risk factors, SLE prevalence within the patient’s
demographic population, and other epidemiological data. Clinical expertise is also crucial
as a highly heterogeneous disease such as SLE can be easily missed or misdiagnosed [1,
51, 89]. Some clinical manifestations are strongly associated with SLE and are therefore of
high diagnostic significance such as alopecia, leukopenia, neurological involvement, oral
ulcers, and serositis [51].
Nevertheless, until now no diagnostic criteria have been established for SLE due to extreme
disease heterogeneity where no consistent clinical presentation or degree of disease severity
appears within the cohort of SLE patients [51, 89]. Therefore, clinicians had to refer to a sort
of guidelines to aid proper diagnosis and relied on SLE classification criteria such as the
revised American College of Rheumatology (ACR) classification criteria for SLE for clinical
diagnosis [48, 49].
The ACR classification encompasses a total of 11 criteria for defining SLE including an indi-
vidual criterion for abnormally elevated titers of antinuclear antibodies that are detected by
immunofluorescence immunoassay, which will be described later, or any other equivalent
assay and another criterion specifying immunologic abnormalities that include the release of
aberrant titers of anti-DNA antibodies or anti-Sm antibodies [48]. Based on ACR, at least 4 of
the 11 criteria must be met for a patient to be classified with SLE disease [48]. However, ACR
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criteria are more suited for severe cases of SLE and not patients with mild or moderate
conditions as it includes the most pronounced manifestations and excludes some of the clinical
presentations shown by patients at early or mid-stages which are considered important.
Clinical presentations need to be taken in consideration as SLE is known to be a progressive
disease that tends to exacerbate over time and establish many of the clinical and serological
manifestations in an accumulating manner [1, 90]. Therefore, the ACR classification criteria
have a specificity reaching 96% but with a suboptimal sensitivity of 83% [89]. Specificity here is
defined as the percentage of individuals who are known to be devoid of the disease and test
negative for it, while sensitivity refers to the percentage of patients who are known to have the
disease and test positive for it [91]. With the aim of overcoming the limitations of the ACR
classification, the Systemic Lupus International Collaborating Clinics (SLICC) classification
criteria have been set in 2012 to encompass many of the clinical manifestations overlooked by
ACR to reach a total of 17 criteria instead of 11 where at least 4 out of the 17 criteria must be
met for a patient to be classified with SLE [50]. In SLICC, the antinuclear antibody criterion
was not changed. However, the immunologic abnormalities criterion in ACR has been sepa-
rated into individual criteria including a separate criterion for abnormal titers of anti-DNA
antibodies but with a more strict cutoff value and a separate criterion for anti-Sm antibodies
highlighting the importance of such autoantibodies in the diagnosis of SLE [50]. Nevertheless,
despite an increase in sensitivity to reach 97% in SLICC compared to 83% in ACR, the
specificity has been reduced to 84% compared to 96% in ACR [50]. Moreover, SLICC criteria
did not improve the inclusion of SLE patients at early stages except for patients with renal
nephritis damage [92].
However, it should be noted that relying on classification criteria for diagnosis is actually
problematic as both disease classification and diagnosis do not generally share the ultimate
aim [89, 91]. Diagnosis aims at identifying a patient’s illness in terms of its causes and nature
and is based on a set of diagnostic criteria that include a number of clinical symptoms and
investigations that are used routinely for guiding the clinical care of patients [91]. Therefore,
diagnostic criteria should have nearly 100% specificity and sensitivity [89, 91]. On the other
hand, classification criteria are basically established to define a total population of patients
having a specific disease that can be recruited for clinical research. They, therefore, encom-
pass the most prominent and prevalent manifestations dropping out the rarer or less com-
mon symptoms and thus typically enjoy high specificity but at the expense of sensitivity.
Consequently, using classification criteria for diagnosis can easily miss or overlook patients
with the disease [1, 89, 91].
With the emergence of new biomarkers that are strongly associated with SLE pathogenesis
as described above, it is highly suggested that these biomarkers will reserve their places in
future developments and optimization in diagnostic criteria next to autoantibodies which
will not only aid accurate diagnosis but will significantly guide patients’ clinical care and
management. The increasingly accumulating data in SLE biomarkers will need to be
paralleled with the development of new sensitive and reliable detection technologies that
are able to simultaneously detect disease biomarkers in a rapid, cost-effective, and sensitive
manner [93]. In the next section, current and new trends in diagnostic technologies for SLE
will be discussed.
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4. Diagnostic technologies
Abnormally elevated titers of antinuclear antibodies are one of the important factors involved
in SLE pathogenesis [4] and are set as stand-alone criterion in both ACR and SLICC classifica-
tion criteria used for SLE diagnosis [48, 50]. Out of these antinuclear antibodies, antibodies that
target double-stranded DNA are highly specific to SLE and are considered the serological
hallmark for SLE [27]. Numerous technologies have been described for the detection of such
autoantibodies in the sera, plasma, or other body fluids of SLE patients where some of them
date back to the 1950s, and until now various state-of-the-art technologies are being described.
In principle, all assays assess the formation of immune complexes between the autoantibodies
and the test antigens which can comprise isolated DNA, complex nuclear mixtures, or an array
of purified, recombinant, or synthetic proteins or peptides [27, 44]. These assays, however,
differ in many factors including the source of the antigenic substrate, the presentation of such
substrates to the autoantibodies where they could be immobilized on solid surfaces or move
freely in solution, the methodology encountered for detecting binding and the employed
reaction conditions [27, 54]. The variations among the detection assays happened to give
conflicting results for the same patient sample where one assay gave positive detection and
another had it negative [94–96]. The most important causation of such result variability
amongst the different assays is the affinity of autoantibodies towards the test antigen which is
highly influenced by the reaction conditions. For example, some assays, as will be described
shortly, favor the recovery of low-affinity antibodies such as ELISA, while others assays favor
the recovery of high-affinity antibodies such as the Farr assay [27, 97].
Another important aspect with regards to the conflicting results obtained from the distinct
assays is the diffidence in the cutoff values set by different assay for considering autoantibody
levels detected significant making data from different assays difficult to compare [27]. This
confusion actually roots from the vague definition of antinuclear or anti-DNA antibody posi-
tivity described in SLICC [50]. The criteria state that an anti-DNA antibody test result is
considered positive if it is higher than the laboratory’s reference range except for ELISA in
which a test result is only positive if it is two times or more the value of the laboratory
reference range [27]. That said, the criteria did not define specific tests and did not refer to
accepted levels for assay sensitivity or specificity [50, 98].
These discrepancies add to the confusion of diagnosticians who already face many challenges
with SLE diagnosis and urge the need for standardization among the different assays. Simplic-
ity, time, and costs are important factors for an assay to be chosen for routine clinical use in
laboratories [27].
Amid all the available assays and newly developed technologies that are described for
detecting anti-DNA antibodies as the most prominent biomarkers for SLE, an important
question is issued of which assay to choose and is there a gold standard to refer to? It has been
reported that assays that can specifically detect high-affinity antibodies as being reflective of
mature immune responses are preferred by many investigators such as the Farr assay or CLIFT
[27, 54]. However, the contribution of high-affinity and low-affinity anti-DNA antibodies to
Rapid Test - Advances in Design, Format and Diagnostic Applications72
SLE pathogenesis is not yet known, and therefore looking for other biomarkers that can arise
from the multiple pathways contributing to SLE pathogenicity is highly needed to comple-
ment the value of anti-DNA antibodies in diagnosis and prognosis of SLE [27, 54].
In this section, the most prominent techniques employed for the detection of antinuclear
antibodies and anti-DNA antibodies that have been described decades ago till today will be
presented, in addition to some investment on the futuristic highly promising state-of-the-art
technologies. However, before proceeding with the discussion of the different assays, a
description of the DNA substrate antigenic properties and the factors that influence such
antigenicity will be discussed as they are important dynamics in assaying anti-DNA anti-
bodies.
4.1. DNA substrate
There are general characteristics of DNA that made it possible to employ DNA isolated from
distinct sources including viral, bacterial, mammalian, and even flagella as the antigen sub-
strates in multiple anti-DNA antibody detection assays [27, 54]. For instance, DNA is generally
a highly charged polymeric molecule with repetitive charges that constitute an important
factor of DNA epitopes that are targeted by anti-DNA antibodies. In addition, all double-
stranded DNA isolated from natural origins predominantly exist in the B-form conformation
rendering them recognizable by anti-DNA antibodies [27].
That said, there are some factors that can influence DNA antigenicity rendering it more or less
antigenic and can thus consequently influence the performance of detection assays [94]. For
instance, single-stranded DNA has a much more flexible structure than DNA double helix
which tends to be more rigid, and thus targeted epitopes are more exposed in the single-
stranded forms making it more antigenic [94]. Another factor that can influence DNA antige-
nicity is size. Anti-DNA antibodies bind DNA through a mechanism called monogamous
bivalency in which both Fab fragments of the same antibody bind the same polynucleotide
chain to ensure stable binding [27]. The distance between two Fab sites is 136 angstroms which
corresponds to a stretch of 40 bp (Figure 2) [27]. Therefore, short oligonucleotides can be
inefficient for binding anti-DNA antibodies, and longer DNA substrates can be essential for
binding [27, 94]. Furthermore, certain isolated DNA such as that from Crithidia luciliae proto-
zoal cells display a bent conformation resembling that of nucleosomes allowing binding only a
subset of autoantibodies [27].
4.2. Immunofluorescence assay (IFA)
IFA (also known as indirect IFA) is an assay that dates back to the 1960s that was developed
with the aim of providing sensitive and reliable means for the detection of ANAs [99]. As
mentioned earlier, ANA positivity is one of the classification criteria described for SLE diag-
nosis, and IFA was mentioned by name in the ACR classification for detecting ANA [48].
Moreover, it is considered the gold standard for ANA testing [44, 48, 49, 90]. IFA involves
fixation of culture cells on a slide to serve as the source of antigens targeted by ANAs, and
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HEp-2 cells are currently employed for this purpose as they express a wide spectrum of
antigens (Figure 3) [44]. Fixed cells are then incubated with serial dilutions of the patient’s
serum or plasma to promote the formation of immune complexes which is then followed by
washing off unbound antibodies. The formed immune complexes are then detected by adding
an anti-IgG antibody that is conjugated with a fluorescent agent and are visualized by fluores-
cence microscopy [44]. Positivity is assigned through determining the endpoint titer which is
defined as the reciprocal of the last dilution that gave a fluorescence signal above the cutoff
value [44, 100]. The specificity of binding can be inferred from examining the staining pattern
which reflects the relative location of the antigen [44].
However, IFA is challenged by certain limitations that can compromise its specificity. First,
whole cells are used as the source of test antigens which leads to the detection of other
Figure 2. Monogamous bivalency binding of anti-DNA antibodies to DNA. Anti-DNA antibodies bind to the DNA via a
mechanism known as monogamous bivalency in which both Fab sites bind the same stretch of polynucleotides. The
distance between two Fab sites is 136 angstroms which corresponds to 40 base pairs. Accordingly, DNA fragments of
shorter sizes are not efficient as substrates in anti-DNA antibody assays [27].
Figure 3. Immunofluorescence assay (IFA). IFA starts by fixation of culture cells on a glass slide which serves in
providing the nuclear antigens that are targeted by ANAs in the patient’s serum. Next, different dilutions of the patient’s
serum are incubated with the cells and are followed by a washing step to remove unbound antibodies. Immune
complexes are detected by adding fluorescently labeled anti-IgG antibodies which are followed by a second washing step
to remove unbound anti-IgG antibodies. Immune complexes are then visualized and analyzed through fluorescence
microscopy [44].
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antibodies targeting cytoplasmic and mitotic antigens that complicate the analysis [44]. Fur-
thermore, certain antigens can be underexpressed in these cells which limit the detection of
certain autoantibodies [101]. Moreover, IFA execution is subject to variability in experimental
conditions including cell fixation protocols, concentrations of assayed cells, different assays of
the commercially available kits, and the specificity of the anti-IgG antibodies [44]. Therefore,
many efforts have been devoted at formulating other assays that can detect ANAs in a more
robust and less technically demanding fashion and capable of high-throughput screening such
as enzyme-linked immunosorbent assay (ELISA).
4.3. Enzyme-linked immunosorbent assay (ELISA)
ELISA is one of the most renowned techniques that enjoy a high versatility that allowed its use
in a variety of biomedical applications including the detection of ANAs and anti-DNA anti-
bodies in patients with SLE and other autoimmune diseases [102–107]. ELISA is based on
coating a solid surface with the antigens of interest such as DNA substrates or an array of
nuclear antigens so that they are tightly bound and can withstand subsequent washing steps.
After immobilization, the test sample containing autoantibodies such as a patient’s serum is
added to promote binding of autoantibodies with their respective antigens, and the formed
immune complexes can be detected through the addition of an anti-IgG antibody that is either
conjugated with a peroxidase or alkaline phosphatase enzyme or a fluorophore [44, 94].
ELISA has high sensitivity and can detect a wide spectrum of antibodies owing to the effic-
ient exposure of surface-immobilized DNA substrates making them readily available in high
concentrations for binding and can thus capture both high- and low-affinity antibodies [27,
44, 94]. Therefore, ELISA can be a good choice for initial screening [27]. Moreover, it is easy
to perform and allows quick, quantitative, and high-throughput analysis of autoantibodies
[44]. However, ELISA mediates the recovery of low-affinity anti-DNA antibodies which
compromises its specificity to SLE [54]. This can be due to a variety of reasons that can relate
to the reaction conditions and the structure and source of the DNA substrate [54]. In addi-
tion, the increased sensitivity of ELISA leads to the generation of false-positive results due to
cross-reactivity [27, 44].
4.4. Farr radioimmunoassay assay
Farr assay has been first introduced in 1968 for the detection of anti-DNA antibodies [108], and
until now it is preferred by many clinicians for assaying anti-DNA antibodies as it mediates
the selective recovery of high-affinity antibodies which have been described to be reflective of
mature immune responses [27]. The principle of the Farr assay is based on the incubation of a
solution of radiolabeled DNA such as 14C-DNA with patient’s serum sample to promote the
formation of immune complexes between anti-DNA antibodies and the DNA substrate. After
incubation, immune complexes are precipitated with a saturated solution of ammonium sul-
fate, and the fraction of the initial radiolabeled DNA that has precipitated with autoantibodies
is used to indicate the amount of anti-DNA antibodies in the serum sample [109]. With the
ability to only recover high-affinity antibodies, Farr assay exhibits high specificity for SLE, but
consequently its sensitivity is not the best when compared with other assays such as ELISA
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that is able to detect both high- and low-affinity antibodies [27]. In addition, because of the
hazardous radioactive material used in DNA labeling and the troublesome associated with its
disposal, researches aimed at the development and optimization of other assays including
ELISA which at the time suffered inconsistencies with the results owing the lack of standard-
ization protocols with antigen immobilization [93]. However, as will be discussed below,
ELISA has been eventually optimized and became one of the popular biomedical techniques
in assaying autoantibodies [44].
4.5. PEG precipitation assay
In this assay, the same principle of the Farr assay is applied where a solution of radiolabeled
DNA is used as the test antigen for anti-DNA antibodies in the serum sample. However,
instead of using ammonium sulfate for precipitation, polyethylene glycol is used as the pre-
cipitating agent, which mainly leads to the recovery of low-affinity anti-DNA antibodies in
contrast to the Farr assay [110].
4.6. Crithidia luciliae immunofluorescence test (CLIFT)
CLIFT is an assay that was first introduced in 1975 [111], and it is similar to the IFA assay
described above except for the source of the used antigenic substrate. The assay employs
Crithidia luciliae protozoal cells as the source of antigenic DNA substrate as they possess a
giant mitochondrion called kinetoplast that contains a giant mass of mitochondrial DNA. The
kinetoplast was considered as a good substrate for the detection of anti-DNA autoantibodies
because it is unlikely to be associated with nuclear antigens and can thus serve as a source of
naked double-stranded DNA [111]. The assay proceeds exactly as IFA where the Crithidia
luciliae cells are fixed on a glass slide and a series of dilutions of the patient’s serum is
incubated with the cells and detection is mediated through the addition of fluorescently
labeled anti-IgG antibodies. CLIFT has been described to be highly specific to SLE similar to
the Farr assay [97]. However, DNA of Crithidia luciliae was described to have a bent conforma-
tion similar to nucleosomal DNAwhich can result in the recovery of only a subset of anti-DNA
antibodies, and thus the assay was described to have a low sensitivity [27, 97].
4.7. Multiplex assays
Multiplex assays refer to the technologies that permit the simultaneous profiling of a repertoire
of antigens in just a single test [112]. In the context of SLE where patients can express as many
as 200 distinct antibodies targeting multiple antigens [44], such multiplex technologies provide
concomitant determination of antibody specificities in a high-throughput, rapid, and cost-
effective manner and can be highly advantageous in the discovery of novel biomarkers and
monitoring disease activity [52, 93, 112]. Multiplex assays involve different settings in which
some of them are already implicated in clinical use such as LINE immunoassays and micro-
beads assays, while other newer multiplex technologies are also rapidly evolving such as
microfluidics and nanobarcodes [93, 112].
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4.7.1. LINE immunoassays (LIA)
In LIA, selected distinct antigens that can be synthetic, recombinant, or purified proteins or
peptides are immobilized onto a nylon membrane or other protein-binding surfaces. Individ-
ual antigens are attached in parallel “lines”where each line represents a specific antigen. These
lines are then cut from the membrane forming thin strips. The same serum sample is then
added to each individual strip to identify all autoantibodies reactive against the panel of strips.
The formed immune complexes are detected through the addition of a secondary antibody
that is conjugated to an enzyme or a fluorescent label. Therefore, LIA allows the simultaneous
detection of multiple autoantibodies in the same patient sample [44, 112].
4.7.2. Addressable laser bead immunoassays
Addressable laser bead immunoassays (Figure 4) [112] are based on coupling distinct antigens
(up to 100) onto microbeads that come in multiple laser reactive colors where each antigen is
coupled to a specific color of beads creating an “addressable” color code that is used for the
identification of each antigen [93]. After antigen coupling, all beads are stabilized, collected
into a microtiter well, and incubated with the sample, and the formed immune complexes are
detected by a fluorescently tagged secondary antibody. Samples are then analyzed using a
dual laser system that utilizes flow cytometry and digital signal processing. Each bead is hit
with two laser beams where one detects the specific color code or address of the microbead
that is used to identify the specific antigen, and the other laser beam detects and quantifies the
fluorescence signal coming from the secondary antibody. The generated data provides quanti-
tative and qualitative analysis of each autoantibody [93].
Both LIA and addressable laser bead immunoassays use defined sets of identified antigens
which allows the detection of specific autoantibodies associated with a certain disease such
as anti-DNA antibodies in SLE which is of high diagnostic value and can thus overcome one
of the main limitations of IFA and ELISA in which assigning absolute specificities to an
Figure 4. Addressable laser bead immunoassay (ALBIA). (A) ALBIA involves coupling of each individual antigen onto
microbeads of laser active color so that antigens can be “addressable” by the color of the beads. (B) After coupling, all
beads are combined into the microtiter well where they are incubated with the test sample such as patient’s serum sample
to promote formation of immune complexes which are detected by a secondary antibody that is fluorescently labeled. (C)
Autoantibody-antigen complexes that are coupled to the beads are analyzed using a dual laser system where one detects
the specific color code of the microbead and can thus be used to identify the specific antigen and the other laser beam
detects and quantifies the fluorescence signal coming from the bound secondary antibody [112].
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ANA-positive result is not possible. Furthermore, these assays are less time-consuming, are
amenable for automation, and allow high-throughput analysis. However, this specificity stem-
ming from the use of defined set of antigens can come at the expense of sensitivity where many
autoantibodies can be missed. For example, SLE patients can release up to 200 different
autoantibodies where only few of them are detected [113].
4.7.3. Autoantigen microarrays
Autoantigen microarrays are high-throughput assays that allow simultaneous detection of dif-
ferent autoantibodies in autoimmune diseases including SLE (Figure 5) [52]. The technique
involves printing a distinct array of antigens into a surface that is coated with substrate that
becomes covalently attached to the antigens. Printed antigens on the surface of microarrays are
performed in a way that retains their reactivity with other molecules. In SLE, the array of
antigens can include nuclear antigens including RNA and DNA and associated proteins, other
cellular proteins, and specific targeted epitopes where the immobilized antigens can be purified
or recombinant proteins or synthetic peptides. Different samples can be screened including
serum, plasma, or other biological fluids such as cerebrospinal fluids or saliva for simultaneous
detection of autoantibodies. Identification of immune complexes is mediated through the addi-
tion of secondary antihuman antibodies that are fluorescently labeled. Distinct isotypes of
Figure 5. Simultaneous detection of autoantibodies using autoantigen microarrays. (A) Multiple autoantigens are printed
onto a microarray surface and are incubated with patients’ serum sample that contains autoantibodies. The formed
immune complexes are identified through the addition of secondary antibodies that are labeled with a fluorophore so
that each spot with a positive reaction produces a fluorescent signal. (B) Different isotypes of autoantibodies such as IgG
and IgM can be visualized using secondary anti-IgG and anti-IgM that are labeled with differently colored fluorophores
such as Cy5 and Cy3. Merging the images will show the different isotypes in the same sample [52].
Rapid Test - Advances in Design, Format and Diagnostic Applications78
autoantibodies such as IgG, IgM, or others can be specified by using secondary antibodies that
are conjugated to different colored fluorophores. Autoantigen microarrays are not only useful in
showing the differential detection of autoantibodies, but specific associations of certain autoanti-
bodies with certain SLE manifestations can be made in addition to the identification of novel
biomarkers. However, microarray chips can be challenging to be produced in consistent and
reproducible manner for commercialization.
4.7.4. Microfluidics and nanobarcodes
With the aim of developing assays that are highly amenable for automation and point-of-care
usage with the ability to concomitantly detect many analytes that are prepared in minute
volumes with very high sensitivity, technologies such as microfluidics and nanobarcodes are
implemented as bioassays for many molecules including the detection of autoantibodies in
autoimmune diseases [112, 114, 115]. These assays are not yet implemented in clinical use, but
they are highly promising as near-future diagnostics.
Microfluidics (also known as lab-on-a-chipmicrotechnologies) from its name is a technology that
involves the analysis of ultra-low amounts of sample that are applied into specific devices that
are fabricated to be in tens to hundreds of micrometers in dimensions [112]. These devices can be
made in different configurations such as channels, pumps, pipes, or valves. The technology of
microfluidics makes use of the flow characteristics of fluids in such micro-sized channels such as
laminar flow and increased surface tension and capillary forces to move the sample through the
microdevice [116]. In the detection of autoantibodies, the walls of such microdevices are coated
with an array of antigens, and sample containing autoantibodies is applied to flow through the
microdevice where immobilized antigens catch their respective antigens. A washing step is then
applied to remove unbound antibodies followed by the application of a labeled secondary
antibody, and signal can be detected by specific detectors [112, 114].
Nanobarcodes fall under the bigger science of nanotechnology in which systems, devices, or
materials are fabricated in the nano-range to render them new and enhanced properties [117].
Unlike microfluidics that are fabricated at the micron scale, nanobarcodes are made even
smaller to the nanoscale [117]. In the detection of autoantibodies, nanobarcodes consist of
different stripes where each stripe is composed of a different metal such as gold, silver,
platinum, or nickel that are electroplated into templates [115]. Different antigens are coupled
to each metal stripe which are then incubated with the serum sample allowing the binding of
each autoantibody to its respective coupled antigen. Detection of immune complexes is
achieved via the addition of secondary antibody that is fluorescently labeled, and different
antigens can be identified by fluorescence microscopy through the differential reflectivity of
each stripe creating a pattern that resembles that of a barcode [112, 115, 117].
Microfluidics and nanobarcodes offer many advantages including the application of minute
amounts of the sample and reagents which reduce costs and minimize chemical waste. More-
over, these devices are amenable to complete automation and maybe well applied as point-of-
care diagnostics without the need of specialized labs and technical skills. In addition, they
produce data that allow simultaneous comparison of the different analytes and at the same
time reliable due to the inclusion of multiple internal controls [112, 115, 116].
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5. Personalized therapy in SLE
SLE is actually a highly representative model for diseases that are in crucial need for personal-
ized therapies as it is one of the highly heterogeneous and complex human diseases with
chaotic pathogenesis [1, 4]. Although under the same disease umbrella, SLE patients are not
homogenous cohorts that can be classified, treated, or managed equally as they show marked
discrepancies in their responses to the same treatment, manifestations of disease severity, type
and levels of circulating biomarkers, organ involvement, and the underlying pathogenic mech-
anisms that are highly influenced by genetic, environmental, and other risk factors [1, 118].
Currently, SLE patients are routinely treated with potent immunosuppressive agents that can
cause adverse side effects which tend to be even more aggressive than the disease itself [41].
With the aim of achieving optimum management of SLE patients, it is therefore very wise to
stratify these patients into subsets that share common pathogenic pathways which can be best
accommodated with targeted or personalized therapeutic approaches that do not only increase
treatment efficacy but also present safer alternatives to the nonselective immune-toxic steroids
that are currently employed for the management of SLE patients [3, 118].
Recent gains in understanding SLE immunopathology have exposed certain deregulated
immune trends that are now known to be common in subsets of SLE patients where some of
these trends are now well characterized and paved the way for the exposure of various targets
that are highly promising in personalized therapeutic approaches (Figure 6) [3]. Over the past
10 years, various medications made their way through preclinical and early clinical testing for
the treatment of SLE patients, but unfortunately almost none of them was met with success
during the later stages of clinical trials. This can be attributed to the highly heterogeneous nature
of SLE patients which make study designs for clinical trials a very difficult mission [119, 120].
In this section of the chapter, highly promising therapeutic targets for specific subsets of SLE
patients and recent therapeutic developments that hold a great potential in personalized
medicine targeting specific cohorts of SLE patients will be discussed.
5.1. New potential therapeutic targets in SLE
As previously learnt, type I IFNs including IFN-α are greatly implicated in SLE pathogenesis
and mediate a variety of downstream-deregulated immune responses including the release of
autoantibodies [4]. However, highly elevated levels of type I INFs are only found in 40–50% of
SLE patients constituting a subset of patients that can be particularly responsive to therapies
targeting type I INFs and other mediators implicated in their pathway such as TLRs and IFN
receptors [118, 121, 122]. One such agent is the anti-IFN-α monoclonal antibody sifalimumab
which showed promising clinical activity in phase I and phase II clinical trials with high
tolerance and safety profile [3, 123]. Other agents include the monoclonal anti-IFN-α anti-
bodies rontalizumab [124] and AGS-009 which have finished phase II and phase I studies,
respectively, with promising clinical results [3].
Another promising target is BAFF cytokine (also called BLyS) which is essential for B-cell
maturation and function [4]. Differential circulating levels of this cytokine have been observed
among SLE patients of different ethnic backgrounds where it was particularly elevated in
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patients of African background in comparison to patients of European background [125]. One
of the agents that has gained approval in many countries for the treatment of SLE patients is
the anti-BAFF monoclonal antibody belimumab [3] that has shown considerable efficacy and
tolerability in randomized placebo-controlled phase III clinical trials in SLE patients against a
control group [55, 126]. Many other agents that target BAFF are also still under clinical
investigations and have shown promising results including blisibimod which has currently
passed phase II clinical trials for SLE [3, 127]. Another agent that target B cells and showed
highly encouraging early results for the treatment of SLE but has unfortunately failed in
advanced stages of clinical trials is the chimeric antibody Rituximab [3]. Rituximab showed
highly promising results in reducing SLE activity particularly in patients with lupus nephritis
[128, 129] and has been largely prescribed to SLE patients all over the world with a decision
that was mainly based on clinical experience and open-label studies [3]. However, in random-
ized placebo-controlled clinical trials, rituximab failed to provide efficacy in moderate to
severe SLE patients with and without renal nephritis [130, 131]. Nevertheless, these results
could be potentially misleading owing to some issues in the study design as it was shown that
both test and control groups were receiving strong immunosuppressive agents including high
doses of glucocorticoids [3, 118]. Nevertheless, rituximab is still prescribed by some clinicians,
which also suggests the probability that this treatment works best at certain subsets of lupus
patients, and further investigations should be implemented [118].
Figure 6. Several therapeutic approaches target distinct immune modulators in the pathogenesis of systemic lupus
erythematosus. Deregulated immune cascade in SLE involves activation of TLRs in plasmacytoid dendritic cells mediated
by internalized nucleic acids that are released from dead cells. Activated TLR induces potent release of type I INF such as
INF-α which activates myeloid cells that act to release elevated amounts of the B-cell activator factor BAFF (also called
BLyS). BLyS stimulates B-cell maturation and release of autoantibodies. Further activation of B cells is mediated via B-cell
and T-cell interactions that can ultimately lead to loss of immune tolerance. Several agents have been described for
targeting key players in the above immune cascade where some have paved their way in clinical use; others are still
under clinical investigations, while some were not met with clinical successes [3].
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Finally, T cells and associated stimulatory pathways play a key role in the deregulated immune
cascade in SLE pathogenesis [1, 4] and are thus highly promising therapeutic targets in SLE.
Many attempts have been made in generating therapeutics targeting T cells including anti-
CD40 ligand antibodies such as CDP7657 which is currently under clinical investigations in
phase I study for SLE [3]. Other anti-T-cell approaches are being attempted including small
molecule inhibitor drugs such as quinoline-3-carboxamide derivatives [132] and analogues of
sphingosine-1-phosphate [133] which are still under clinical developments.
6. Conclusion
SLE is a chronic and highly progressive autoimmune disease that carries a high risk of early
death [1–3]. The incidence and prevalence of SLE are highly influenced by many factors such
as race, ethnicity, age, gender, and patients’ demographics [6]. Although informative reporting
on SLE epidemiology is inconsistent among the different countries, it is recognized as a global
disease that faces so many clinical challenges in its diagnosis, prognosis, monitoring, and
management [1]. The challenging nature of SLE originates from its chaotic immunopathology
in which the affected stage in the immune cascade and the extent of deregulation are highly
variable among SLE patients who as a consequence express a wide array of nonhomogeneous
highly protean clinical and serological manifestations making them impossible to be recog-
nized as a single cohort of patients that can be managed equally [1, 4]. Consequently, setting
specific diagnostic criteria is very challenging, and until now no defined diagnostic guidelines
have been established for SLE [51, 89]. However, as a reference, clinicians have used SLE
classification criteria for diagnostic purposes such as the ACR or the more recent SLICC [48,
49, 92]. Nevertheless, using classification criteria for diagnosis is problematic because they are
set to include the most prevalent manifestations of the disease that occur during late or severe
stages and neglect many of the early or mid-stage symptoms making them highly specific but
not sensitive [89, 91]. This cannot be well suited for SLE owing to its progressive nature where
many of its pathologies accrue overtime and therefore referring to classification criteria for
diagnosis can dismiss many SLE patients specifically those at the early stages of the disease [1,
89, 91]. Another challenge facing SLE is the insufficient availability of reliable and specific
biomarkers which are highly needed for the highly heterogeneous nature of SLE where it is
highly improbable that only a single biomarker can be indicative of the wide array of manifes-
tations [5]. Therefore, the search for distinct and specific biomarkers that can accurately
mediate early diagnosis, predict disease development and emergence of disease flares, monitor
disease activity, indicate specific organ damage, and guide therapies, guide reliable inclusion
in eligibility criteria for conducting clinical trials, and evaluate patients’ responses to novel
therapeutics is highly needed and never ceased [5, 43]. Conventionally, ANAs and anti-DNA
antibodies are routinely used as biomarkers for SLE as they occur in at least 70 and 95% of SLE
patients, respectively, and their detection is included in the classification criteria for SLE [48,
50, 51]. However, ANAs are highly unspecific for SLE as they are detected in other autoim-
mune diseases in addition to a not so small proportion of the general population [44]. Anti-
DNA antibodies are currently the most specific biomarkers for SLE, and their detection outside
SLE is not yet found [27]. Nevertheless, anti-DNA antibodies are poor predictors for SLE
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activity as it happens that elevated levels of anti-DNA antibodies accompany patients in
remission while normal levels accompany flared disease activity [45, 59, 61, 62]. Many prom-
ising novel biomarkers are emerging such as type I INFs which are highly elevated in a subset
of SLE patients or some epigenetic biomarkers that are associated with SLE progression such
as DNA methylation pattern, microRNA expression, and various histone modifications [5].
However, efforts devoted to overcome the abovementioned challenges of SLE along those
employed at the discovery of novel biomarkers will not be possible without being rivaled with
developments in state-of-the-art technologies that can accurately detect and monitor bio-
markers with high sensitivity and specificity and in a manner that is cost-effective, rapid, easy
to perform, and amenable to high-throughput screening [27, 44]. Currently, many of the
technologies available for SLE diagnosis and monitoring are set to detect ANAs and anti-
DNA antibodies [27, 44]. According to many investigators, the Farr assay is considered the
gold standard for being able to detect high-affinity autoantibodies which are described to be
more reflective of mature immune responses [27]. Nevertheless, a variety of techniques are
available that all set to measure the formation of autoantibody-antigen immune complexes but
differ in the source of the antigenic substrates, the way that such substrates are being exposed
to the autoantibodies in the sample, the employed reaction conditions, and in the principle of
detection [27, 54]. These discrepancies in the setup of the distinct assays render the differential
sensitivities and specificities toward the recovered or detected autoantibodies in which a
particular autoantibody can be tested positive in one assay and negative in another for the
same sample [94–96]. The most important contributor for such conflicting results is the affinity
of autoantibodies where some assays employ reaction settings that favor the recovery of low-
affinity antibodies such as ELISA, while others favor the recovery of high-affinity antibodies
such as the Farr assay [27, 97]. Therefore, the results obtained from different assays are difficult
to compare and add to the confusion already facing SLE diagnosis. With the emergence of
novel biomarkers, the need for multiplex technologies that permit the simultaneous detection
of many antigens in just a single test in a rapid, cost-effective, and high-throughput fashion
intensifies to accommodate the multiple parameters introduced with the increased variability
of detected biomarkers [112, 113, 134]. Many multiplex technologies such as autoantigen
arrays, nanobarcodes, microfluidics, and addressable laser immunoassays are strongly emerg-
ing with a highly promising potential for clinical diagnosis and monitoring of SLE [93, 112].
Finally, SLE most accurately exemplifies a disease model that in crucial need for the develop-
ment of personalized therapies owing to the highly versatile clinical manifestations of SLE
patients who are not possible to be treated equally [3, 118]. Potent immunosuppressants are
currently employed for the nonspecific management of SLE patients, but they are associated
with many adverse side effects that can even be more aggressive than the disease itself [41].
The better understanding of SLE pathophysiology has helped in stratifying SLE patients into
subsets that share common immune-pathologies and thus can guide many of the emerging
highly promising personalized therapeutic approaches [3, 118].
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